CEDAR KNOLLS, N.J.,
June 4, 2020 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS") (NASDAQ: MYOS), a
bionutrition company and the owner of
Fortetropin®, a proprietary bioactive composition
that helps build lean muscle, announced today that it will be
launching an online continuing education ("CE") course, titled,
"Small Animal Sarcopenia: A Neglected Syndrome of Importance
to Cats and Dogs" for veterinarians and veterinary
technicians. The course has been approved by the American
Association of Veterinary State Boards ("AAVSB") for inclusion
in its Registry of Approved Continuing Education
("RACE") programs.
All states require that veterinarians and veterinary technicians
complete continuing education courses on a regular basis. MYOS is
pleased to offer its RACE-Approved CE Course to
veterinarians and veterinary technicians on small animal muscle
health free of charge. In addition to discussing the
diagnosis and impact of sarcopenia on small animals, the CE course
will include a comprehensive discussion on pharmaceutical and
nutrition clinical trials in veterinary medicine that focuses on
addressing muscle loss. After successful completion of the CE
course, veterinarians and veterinary technicians will receive 1
hour of CE credit toward their AAVSB CE requirements.
"Muscle health is an area that has not received the attention
that it deserves in both human and veterinary medicine. Both
human and veterinary clinical studies have shown that muscle loss
can have a major impact on lifespan and quality of life for humans
and animals. By offering this course to veterinarians and
veterinary technicians at no cost, we hope to bridge
this knowledge gap. This is the first course of many we
intend to offer to veterinarians. Educating clinicians on the
importance of muscle health is a priority for us as we expand our
animal health business," commented Joseph
Mannello, CEO of MYOS.
The course will be offered on June
10 and 11, 2020 at both 12 pm
(EDT) and 3 pm (EDT).
There is no fee to register. The course will be delivered via
the Zoom platform. Veterinarians and veterinary technicians
can register for the course at the following links:
Small Animal Sarcopenia: A Neglected Syndrome of Importance
to Cats and Dogs
1) June 10, 2020 @ 12 pm (EDT):
https://zoom.us/webinar/register/WN_DsJceM7CQ86St_-9cPRMJw
2) June 10, 2020 @ 3 pm (EDT):
https://zoom.us/webinar/register/WN_Sru7LYLRTA-4CTj4JxoQkQ
3) June 11, 2020 @ 12 pm (EDT):
https://zoom.us/webinar/register/WN__cB_NztvRDGPY6tAwQ6aZQ
4) June 11, 2020 @ 3 pm (EDT):
https://zoom.us/webinar/register/WN_eYxvhZ_HTS6c7lfrk5kQTQ
About MYOS RENS Technology Inc.
MYOS RENS Technology
Inc. (MYOS), "The Muscle Company®", is a Cedar Knolls, NJ-based advanced nutrition
company that develops and markets products that improve muscle
health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size, lean body mass and reduce muscle atrophy.
MYOS believes Fortetropin has the potential to redefine existing
standards of physical health and wellness. For more information,
please visit www.myosrens.com.
About the American Association of Veterinary State Boards
(AAVSB) and RACE Programs
The mission of the AAVSB is to
support and advance the regulatory process for veterinary medicine.
Their vision is to be the primary source for comprehensive
information that strategically strengthens the veterinary
regulatory community. The Registry of Approved Continuing
Education (RACE®) is one of the key programs
provided by the AAVSB. The purpose of the RACE program is to
develop and apply uniform standards related to providers and
programs of continuing education (CE) in veterinary
medicine.
Forward-Looking Statements
Any statements in
this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the success of our products,
including MYOS Canine Muscle Formula®, MYOS'
Physician Muscle Health Formula®, BodyLogicMD Muscle
Formula, Yolked®,
Qurr®, and MYOS Enteral
Nutrition Formula™, the success of our research and
development, the results of the clinical evaluation
of Fortetropin® and its effects, the
ability to enter into new partnership opportunities and the success
of our existing partnerships, the ability to enter into new
distribution agreements, the ability to generate revenue and cash
flow from sales of our products, the ability to increase our
revenue and gross profit margins, the ability to achieve a
sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock
Market, risks in product development, our ability to raise capital
to fund continuing operations, the adverse impact of the COVID-19
pandemic on the economy and our business, and other factors
discussed from time to time in our filings with the
Securities and Exchange Commission. We undertake no obligation to
update or revise any forward-looking statement for events or
circumstances after the date on which such statement is made except
as required by law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
MYOS RENS Technology
Joanne Goodford
Phone: 973-509-0444
Email: jgoodford@myoscorp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-launches-race-approved-continuing-education-course-for-veterinarians-on-june-10-2020-301070522.html
SOURCE MYOS RENS Technology